drugset / Trial / NCT06769490
Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia
NaSingle-groupOpen-labelTreatment
Summary
The goal of this all-oral combination is to deliver safe and effective therapy for the largest portion of AML subtypes (NPM1mt, KMT2Ar, NUP98r \~ 40-45%).
Timeline
- Start
- 2025-07-10
- Primary completion
- 2028-09-15
- Completion
- 2030-09-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Quizartinib | Small molecule | — | — |
| Subject | Ziftomenib | Small molecule | — | — |